Tandem Diabetes Care Inc Revenue Growth Rates (TNDM), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Tandem Diabetes Care Inc   (NASDAQ: TNDM)
 

TNDM's Revenue Growth by Quarter and Year

Tandem Diabetes Care Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TNDM Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 254.56
1st Quarter March 246.79
FY 501.35

TNDMs Annual Revenue
Tandem Diabetes Care Inc 's Revenue in the fiscal year 2025 $ 1,014.01 millions
Tandem Diabetes Care Inc 's Revenue in the fiscal year 2024 $ 939.57 millions
Tandem Diabetes Care Inc 's Revenue in the fiscal year 2023 $ 747.69 millions
Tandem Diabetes Care Inc 's Revenue in the fiscal year 2022 $ 801.22 millions
Tandem Diabetes Care Inc 's Revenue in the fiscal year 2021 $ 702.80 millions




TNDM Revenue second quarter 2026 Y/Y Growth Comment
Tandem Diabetes Care Inc reported Revenue growth of 5.77% year on year in the second quarter 2026, to $ 254.56 millions, this is lower than Tandem Diabetes Care Inc 's recent average Revenue improvement of 34.55%.

Looking into second quarter 2026 results within Medical Equipment & Supplies industry 111 other companies have achieved higher Revenue growth. While Tandem Diabetes Care Inc ' s Revenue increase of 5.77% ranks overall at the positon no. 2165 in the second quarter 2026.


TNDM Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 1.84 % 43.53 % -10.75 %
3rd Quarter September - 1.9 % 31.26 % -9.25 %
2nd Quarter June 5.77 % 8.52 % 13.31 % -2.26 %
1st Quarter March 5.28 % 22.3 % 13.16 % -3.71 %
FY   - 7.61 % 25.69 % -

Financial Statements
Tandem Diabetes Care Inc 's second quarter 2026 Revenue $ 254.56 millions TNDM's Income Statement
Tandem Diabetes Care Inc 's second quarter 2025 Revenue $ 240.68 millions Quarterly TNDM's Income Statement


TNDM Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 15.86 % 15.93 % 6.02 %
3rd Quarter September - 3.16 % 9.86 % -5.17 %
2nd Quarter June 3.15 % 2.67 % 15.71 % 15.56 %
1st Quarter March -14.21 % -17.01 % -2.61 % -23.18 %
FY (Year on Year)   - 7.61 % 25.69 % -


Back to TNDM Growth rate Comparisons >> Back to TNDM Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #112
Healthcare Sector #317
Overall #2165

Revenue Y/Y Growth Statistics
High Average Low
173.27 % 34.55 % -92.28 %
(Jun 30 2020)   (Dec 31 2018)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #112
Healthcare Sector #317
Overall #2165
Revenue Y/Y Growth Statistics
High Average Low
173.27 % 34.55 % -92.28 %
(Jun 30 2020)   (Dec 31 2018)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Tandem Diabetes Care Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
135.19 % 10.64 % -46.52 %
(Dec 31 2016)  


TNDM's II. Quarter Q/Q Revenue Comment
Tandem Diabetes Care Inc achieved in the II. Quarter 2026 below company average Revenue growth of 3.15% quarter on quarter, to $ 254.56 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 2.67% in the II. Quarter a year ago.

Within Medical Equipment & Supplies industry 55 other companies have achieved higher Revenue quarter on quarter growth. While Tandem Diabetes Care Inc 's Revenue growth quarter on quarter, overall rank is 1327.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #56
Healthcare Sector #187
Overall #1327
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #56
Healthcare Sector #187
Overall #1327
Revenue Q/Q Growth Statistics
High Average Low
135.19 % 10.64 % -46.52 %
(Dec 31 2016)  


TNDM's II. Quarter Q/Q Revenue Comment
Tandem Diabetes Care Inc achieved in the II. Quarter 2026 below company average Revenue growth of 3.15% quarter on quarter, to $ 254.56 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 2.67% in the II. Quarter a year ago.

Within Medical Equipment & Supplies industry 55 other companies have achieved higher Revenue quarter on quarter growth. While Tandem Diabetes Care Inc 's Revenue growth quarter on quarter, overall rank is 1327.


Tandem Diabetes Care Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 1,037.30 $ 1,023.42 $ 1,011.04 $ 1,005.83 $ 1,001.19
Y / Y Revenue Growth (TTM) 3.61 % 4.19 % 7.61 % 17.79 % 25.8 %
Year on Year Revenue Growth Overall Ranking # 664 # 619 # 1596 # 1531 # 792
Seqeuential Revenue Change (TTM) 1.36 % 1.22 % 0.52 % 0.46 % 1.92 %
Seq. Revenue Growth (TTM) Overall Ranking # 2432 # 1998 # 1295 # 922 # 2533


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Tandem Diabetes Care Inc 's cumulative twelve months Revenue were $ 1,037 millions, company would post below average annual Revenue growth of 1.92% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Tandem Diabetes Care Inc 's Revenue growth from the 246.79% growth in Mar 31 2026.

In the Healthcare sector 137 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 619 to 664.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 129
Healthcare Sector # 138
Overall # 664

Revenue TTM Y/Y Growth Statistics
High Average Low
123.1 %
 24.89 %
-89.36 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 129
Sector # 349
S&P 500 # 2432
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Tandem Diabetes Care Inc 's cumulative twelve months Revenue were $ 1,037 millions, company would post below average annual Revenue growth of -89.36% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Tandem Diabetes Care Inc 's Revenue growth from the 246.79% growth in Mar 31 2026.

In the Healthcare sector 137 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 619 to 664.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 129
Healthcare Sector # 138
Overall # 664

Revenue TTM Y/Y Growth Statistics
High Average Low
123.1 %
24.89 %
-89.36 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 129
Sector # 349
S&P 500 # 2432




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TNDM's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Concentra Group Holdings Parent Inc 10.03%$ 10.030 millions
Lemaitre Vascular Inc 10.02%$ 10.017 millions
Amneal Pharmaceuticals Inc 9.93%$ 9.934 millions
Merit Medical Systems Inc9.79%$ 9.792 millions
Idexx Laboratories Inc9.73%$ 9.728 millions
Lenz Therapeutics Inc 9.72%$ 9.720 millions
Encompass Health Corporation9.58%$ 9.584 millions
Trisalus Life Sciences Inc 9.57%$ 9.567 millions
Amgen Inc 9.53%$ 9.533 millions
Sotera Health Company9.45%$ 9.452 millions
Illumina Inc 9.44%$ 9.443 millions
Stryker Corp9.42%$ 9.415 millions
International Stem Cell Corporation9.32%$ 9.318 millions
Cytosorbents Corporation9.29%$ 9.292 millions
Resmed Inc 9.22%$ 9.222 millions
Fate Therapeutics Inc 9.18%$ 9.177 millions
Bausch and Lomb Corp9.08%$ 9.077 millions
Pacs Group Inc 9.07%$ 9.071 millions
Electromed Inc 8.97%$ 8.968 millions
National Healthcare Corp8.83%$ 8.833 millions
Chemed Corporation8.80%$ 8.800 millions
Tactile Systems Technology Inc 8.76%$ 8.763 millions
Gyre Therapeutics Inc 8.72%$ 8.718 millions
P3 Health Partners Inc 8.60%$ 8.599 millions
Maravai Lifesciences Holdings Inc 8.53%$ 8.534 millions
U S Physical Therapy Inc8.47%$ 8.470 millions
Ocugen Inc 8.38%$ 8.376 millions
Baxter International Inc 8.36%$ 8.363 millions
Carlisle Companies Incorporated8.33%$ 8.334 millions
Universal Health Services Inc 8.27%$ 8.268 millions


About Tandem Diabetes Care Inc Revenue Growth Rates (TNDM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Tandem Diabetes Care Inc (CIK 1438133).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001438133-26-000125
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Tandem Diabetes Care Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.